Tekla Life Sciences Investors Total Assets
Tekla Life Sciences Investors total assets. Based on the latest financial reports, Tekla Life Sciences Investors (HQL) holds total assets worth $563.23 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see HQL stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Tekla Life Sciences Investors (1996–2025)
Total assets of Tekla Life Sciences Investors from 1996 to 2025. This chart illustrates how Tekla Life Sciences Investors's total assets have evolved over time, based on quarterly financial data. See Tekla Life Sciences Investors stock quote for real-time trading data and today's change.
Tekla Life Sciences Investors - Asset Composition Analysis
Tekla Life Sciences Investors Total Assets Breakdown (September 2025)
Tekla Life Sciences Investors total assets breakdown as of September 2025. Tekla Life Sciences Investors's total assets of $563.23 Million consist of 0.2% current assets and 99.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.0% |
| Accounts Receivable | $1.14 Million | 0.2% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1996–2025)
This chart illustrates how Tekla Life Sciences Investors's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Tekla Life Sciences Investors to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tekla Life Sciences Investors's current assets represent 0.2% of total assets in 2025, an increase from 0.2% in 1996.
- Cash Position: Cash and equivalents constituted 0.0% of total assets in 2025, down from 0.2% in 1996.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1996.
- Asset Diversification: The largest asset category is accounts receivable at 0.2% of total assets.
Tekla Life Sciences Investors Competitors by Total Assets
Key competitors of Tekla Life Sciences Investors based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gore Street Energy Storage Fund Plc
LSE:GSF
|
UK | GBX379.67 Million |
|
Sprott Physical Gold Trust
TO:PHYS
|
Canada | CA$14.74 Billion |
|
Industrivarden AB ser. C
ST:INDU-C
|
Sweden | Skr231.37 Billion |
|
Julius Baer Gruppe AG
SW:BAER
|
Switzerland | CHF104.72 Billion |
|
KBC Ancora
BR:KBCA
|
Belgium | €3.63 Billion |
|
Norte Grande
SN:NORTEGRAN
|
Chile | CL$2.96 Billion |
|
Pinnacle Investment Management Group Ltd
AU:PNI
|
Australia | AU$1.49 Billion |
|
A.F.P. Provida
SN:PROVIDA
|
Chile | CL$1.39 Trillion |
Tekla Life Sciences Investors - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.58 | 0.00 | 0.13 |
| Quick Ratio | 2.58 | 0.00 | -23.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.30 Million | $-15.03 Million | $-38.51K |
Tekla Life Sciences Investors - Advanced Valuation Insights
This section examines the relationship between Tekla Life Sciences Investors's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.12 |
| Latest Market Cap to Assets Ratio | 1.07 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | $515.38 Million |
| Market Capitalization | $550.08 Million USD |
Valuation Analysis
Above Book Valuation: The market values Tekla Life Sciences Investors's assets above their book value (1.07x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Tekla Life Sciences Investors's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Tekla Life Sciences Investors (1996–2025)
The table below shows the annual total assets of Tekla Life Sciences Investors from 1996 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-09-30 | $515.38 Million | +11.90% |
| 2024-09-30 | $460.58 Million | +14.40% |
| 2023-09-30 | $402.60 Million | -2.92% |
| 2022-09-30 | $414.73 Million | -22.36% |
| 2021-09-30 | $534.19 Million | +10.33% |
| 2020-09-30 | $484.17 Million | +25.11% |
| 2019-09-30 | $386.98 Million | -19.12% |
| 2018-09-30 | $478.47 Million | +2.16% |
| 2017-09-30 | $468.33 Million | +12.14% |
| 2016-09-30 | $417.63 Million | -10.73% |
| 2015-09-30 | $467.85 Million | +5.17% |
| 2014-09-30 | $444.84 Million | +46.90% |
| 2013-09-30 | $302.82 Million | +33.12% |
| 2012-09-30 | $227.48 Million | +32.57% |
| 2011-09-30 | $171.60 Million | -33.18% |
| 2010-09-30 | $256.80 Million | -3.13% |
| 2009-09-30 | $265.10 Million | -5.66% |
| 2008-09-30 | $281.00 Million | -9.09% |
| 2007-09-30 | $309.10 Million | +14.14% |
| 2006-09-30 | $270.80 Million | +17.59% |
| 2005-09-30 | $230.30 Million | +19.26% |
| 2004-09-30 | $193.10 Million | +0.05% |
| 2003-09-30 | $193.00 Million | +22.23% |
| 2002-09-30 | $157.90 Million | -26.86% |
| 2001-09-30 | $215.90 Million | +112.92% |
| 1998-09-30 | $101.40 Million | -23.30% |
| 1997-09-30 | $132.20 Million | +6.87% |
| 1996-09-30 | $123.70 Million | -- |
About Tekla Life Sciences Investors
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, … Read more